Aripiprazole: a novel atypical antipsychotic acts as stabilizer of the dopamine system

被引：0
|
作者：
Klein, N [1 ]
Wallner, H [1 ]
Kasper, S [1 ]
机构：
[1] Klin Abt Allgemeine Psychiat, A-1090 Vienna, Austria
来源：
PSYCHOPHARMAKOTHERAPIE | 2006年 / 13卷 / 02期
关键词：
aripiprazole; dopamine stabilizer; partial agonist; schizophrenia; bipolar disorder;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aripiprazole is a new atypical antipsychotic with a unique mechanism of action. It is a partial agonist to the D-2 receptor and therefore acts as stabilizer of the dopaminergic system. Aripiprazole has been shown to have good efficacy on (a) treating positive and negative symptoms of schizophrenia and (b) treating bipolar disorders. Furthermore, aripiprazole has a favourable adverse event profile, which in many cases does not differ from placebo.
引用
收藏
页码：49 / +
页数：6
相关论文
共 50 条
  • [21] Pharmacology of aripiprazole, a novel antipsychotic:: dopamine D2 receptor partial agonist
    Kikuchi, T
    Arlene, S
    Yocca, F
    Tadori, Y
    Hirose, T
    McQuade, R
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) : 190 - 190
  • [22] Differential regulation of dopamine receptor subtypes by novel atypical antipsychotic drugs
    Tarazi, FI
    Zhang, K
    Baldessarini, RJ
    JOURNAL OF NEUROCHEMISTRY, 2001, 78 : 80 - 80
  • [23] Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes
    Lawler, CP
    Prioleau, C
    Lewis, MM
    Mak, C
    Jiang, D
    Schetz, JA
    Gonzalez, AM
    Sibley, DR
    Mailman, RB
    NEUROPSYCHOPHARMACOLOGY, 1999, 20 (06) : 612 - 627
  • [24] Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes
    Cindy P Lawler
    Cassandra Prioleau
    Mechelle M Lewis
    Chun Mak
    Dong Jiang
    John A Schetz
    Antonio M Gonzalez
    David R Sibley
    Richard B Mailman
    Neuropsychopharmacology, 1999, 20 : 612 - 627
  • [25] The research and development of the novel antipsychotic aripiprazole
    Kikuchi, Tetsuro
    DRUGS OF THE FUTURE, 2007, 32 : 30 - 30
  • [26] The effectiveness of the novel atypical antipsychotic aripiprazole according to levels of agitation at baseline in patients with acute schizophrenia
    Marder, S. R.
    Crandall, D.
    Pultz, J.
    Carson, W. H.
    Gutierrez-Esteinou, R.
    Tran, Q. -V.
    Marcus, R. N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S277 - S277
  • [27] Effects of dopamine system stabilizer (aripiprazole) for subjective experience in individuals at-risk mental state
    Kobayashi, Hiroyuki
    Morita, Keiko
    Takeshi, Kiyoaki
    Kashima, Haruo
    Mizuno, Masafumi
    EARLY INTERVENTION IN PSYCHIATRY, 2008, 2 : A129 - A129
  • [28] Aripiprazole, a novel antipsychotic, is a potent partial agonist at human dopamine D2 receptors
    Burris, KD
    Molski, TF
    Ryan, E
    Xu, C
    Tottori, K
    Kikuchi, T
    Yocca, FD
    Molinoff, PB
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 88 - 88
  • [29] Aripiprazole, a novel antipsychotic drug, increases dopamine release in the prefrontal cortex and hippocampus in rat brain
    Li, Z
    Ichikawa, J
    Meltzer, HY
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S262 - S262
  • [30] Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder
    Bowden, CL
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 : 12 - 19
12345